Long-term (68 weeks) administration of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: efficacy and safety data from a phase III study
These data confirm the safety of long-term nemolizumab for paediatric patients with AD, and demonstrate improvements in pruritus, skin symptoms, and patient and caregiver QoL over 68 weeks of treatment.
Authors
- Hiroshi Komazaki (ORCID: https://orcid.org/0000-0002-0426-1553)
- Toshio Katsunuma (ORCID: https://orcid.org/0000-0003-2646-3006)
- Atsuyuki Igarashi (ORCID: https://orcid.org/0000-0002-5903-3187)
- Yuko Nagano
Institutions
- Jikei University School of Medicine (JP)
- NTT Medical Center (JP)
- The Jikei University Hospital (JP)
- Maruho (Japan) (JP)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1093/bjd/ljae458
- Citations
- 14
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 7.49